Continued improvement in PFS with iSCIB1+

Summary by AI BETAClose X

Scancell Holdings plc announced updated Phase 2 data for its iSCIB1+ immunotherapy in advanced melanoma, showing a progression-free survival (PFS) of 74% at 16 months, significantly outperforming the standard of care's 50% PFS at 11.5 months. Early overall survival data also indicates a 14% improvement at 26 months over standard of care. The company has received positive regulatory advice and is advancing iSCIB1+ into late-stage registrational trials, targeting 80% of melanoma patients based on specific HLA alleles.

Disclaimer*

UK 100

Latest directors dealings